John is the CEO of Disc Medicine. Previously, John was Chief Business Officer at Acceleron Pharma, where he spent more than thirteen years helping to build the company from a privately-held startup to a public biotech (acquired by Merck & Co. for over $11 billion in 2021). At Acceleron, John served in various roles including General Counsel, Senior Vice President of Corporate Development and finally Executive Vice President and Chief Business Officer. John led the in-licensing of sotatercept for pulmonary hypertension from Bristol-Myers Squibb and helped negotiate the collaboration agreement governing the development and commercialization of luspatercept (now marketed as Reblozyl®️). Prior to Acceleron, John worked at the law firms of Ropes & Gray and Foley Hoag. He received his undergraduate degree from Harvard College, summa cum laude, MSc from Stanford University, PhD from MIT in Biological Sciences, and JD from Harvard Law School.